Boltz raises $110 million to sell drug design by the token. Boltz, the MIT spinout now based in London, has raised a $110 million Series A led by Bessemer Venture Partners, with existing backers Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures, and new investors Greycroft, F-Prime Capital, Hummingbird and Benchling. The round comes less than a year after a $28 million seed. Boltz says paying customers’ molecular token usage has risen 50-fold since June, when it launched its first proprietary models, BoltzMol-1 for small-molecule discovery and BoltzProt-1 for protein design, and that it has partnerships with six of the twenty largest drugmakers, including Pfizer, GSK, Takeda and Bristol Myers Squibb. The company employs about 40 AI researchers in London. No valuation was disclosed.
Lilly’s mevidalen data show a clear miss. Full results from the Phase 2 PRESENCE-ALZ trial, presented as a poster at the CTAD conference, show Eli Lilly’s dopamine D1 receptor modulator mevidalen failed its primary endpoint in 304 patients with mild-to-moderate Alzheimer’s disease in the United States and Japan. The trial required a greater than 60 percent posterior probability that either dose produced at least a 2-point benefit over placebo on the Integrated Alzheimer’s Disease Rating Scale at 24 weeks; the probabilities came in at 14.0 percent for the 25 mg dose and 21.2 percent for 50 mg, with least-squares mean differences of 0.62 and 0.95 points. Adverse event rates were similar across arms, at about 65 percent, though systolic blood pressure rose roughly 8 to 11 mm Hg after dosing. Lilly had already removed the Alzheimer’s programme from its pipeline in its third-quarter update on October 29, saying it did not meet the company’s internal bar; the drug previously missed in Lewy body dementia in 2021.